[
  {
    "question": {
      "question_id": "cs03_q03_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "longitudinal",
      "prompt": "What is driving the hepatic adverse events in this trial?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q03_longitudinal",
      "answer_text": "I cannot find any information regarding the cause of hepatic adverse events in the trial based on the available data [ref_id: not found].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_f56cbb003f654081ba61173d",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 516
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_f56cbb003f654081ba61173d",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_2165b9f8760c4b3f943ef5f0",
              "name": "memory_search",
              "arguments": {
                "query": "hepatic adverse events trial cause",
                "limit": 10
              }
            }
          ],
          "tokens_used": 596
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_2165b9f8760c4b3f943ef5f0",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I cannot find any information regarding the cause of hepatic adverse events in the trial based on the available data [ref_id: not found].",
          "tokens_used": 638
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1750,
      "wall_time_ms": 3272.7541150525212,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q06_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "paraphrase",
      "prompt": "Why are liver enzymes elevated in a subset of trial participants?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q06_paraphrase",
      "answer_text": "I cannot find any information in the memory system explaining why liver enzymes are elevated in a subset of trial participants [ref_id: none]. The search returned no results.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_747569f3d52b4e10967ae6ed",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 516
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_747569f3d52b4e10967ae6ed",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_ff3fe2442d5d448e9909c4a3",
              "name": "memory_search",
              "arguments": {
                "query": "elevated liver enzymes trial participants cause",
                "limit": 10
              }
            }
          ],
          "tokens_used": 597
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_ff3fe2442d5d448e9909c4a3",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I cannot find any information in the memory system explaining why liver enzymes are elevated in a subset of trial participants [ref_id: none]. The search returned no results.",
          "tokens_used": 644
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1757,
      "wall_time_ms": 4624.137190054171,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q07_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "temporal",
      "prompt": "When did ALT elevations first become apparent, and how many weeks elapsed before subjects met Hy's Law criteria?",
      "ground_truth": {
        "canonical_answer": "ALT elevations in the statin subgroup first became apparent during the early signal phase. It took approximately 7-13 weeks from initial detection to subjects meeting Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN) during the escalation phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q07_temporal",
      "answer_text": "I could not find information regarding when ALT elevations first became apparent or the number of weeks elapsed before subjects met Hy's Law criteria [ref_id].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9bb1f9b9f4d34f2f92fe51c9",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 526
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9bb1f9b9f4d34f2f92fe51c9",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_8dd4a6f131704db29313bbcc",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations Hy's Law criteria timeline"
              }
            }
          ],
          "tokens_used": 600
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_8dd4a6f131704db29313bbcc",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find information regarding when ALT elevations first became apparent or the number of weeks elapsed before subjects met Hy's Law criteria [ref_id].",
          "tokens_used": 644
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1770,
      "wall_time_ms": 3881.4009110210463,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q08_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "counterfactual",
      "prompt": "If the Site 07 lab equipment calibration issue were responsible for the ALT elevations, what pattern would you expect across sites? Does that match the data?",
      "ground_truth": {
        "canonical_answer": "If Site 07 equipment were the cause, ALT elevations would be confined to Site 07 and resolve after recalibration. Instead, the ALT signal appears across multiple sites and correlates with statin co-administration, not site. The cross-site pattern rules out a site-specific equipment explanation.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_015",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_024"
        ],
        "key_facts": [
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q08_counterfactual",
      "answer_text": "I could not find any information in memory regarding a Site 07 lab equipment calibration issue or its potential impact on ALT elevations across sites [ref_id: none]. Therefore, I cannot determine the expected pattern or whether it matches the data.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_34f076cc8bff49a9823b0fe2",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 536
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_34f076cc8bff49a9823b0fe2",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_00709af102314d699e7bce71",
              "name": "memory_search",
              "arguments": {
                "query": "Site 07 lab equipment calibration issue ALT elevations pattern across sites"
              }
            }
          ],
          "tokens_used": 616
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_00709af102314d699e7bce71",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information in memory regarding a Site 07 lab equipment calibration issue or its potential impact on ALT elevations across sites [ref_id: none]. Therefore, I cannot determine the expected pattern or whether it matches the data.",
          "tokens_used": 679
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1831,
      "wall_time_ms": 4648.063382017426,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q14_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "paraphrase",
      "prompt": "Why is there a difference in liver enzyme levels between patient subgroups?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy via CYP3A4 inhibition causes hepatotoxicity in the statin subgroup. The signal appears across all sites, not just Site 07, ruling out the equipment calibration hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q14_paraphrase",
      "answer_text": "I could not find any information in the memory system regarding differences in liver enzyme levels between patient subgroups. The search returned no results, and no further data is available to analyze this question.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_c12220e4d9644f5095f864ac",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 518
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_c12220e4d9644f5095f864ac",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_c2deca2f9f244c09aaf9a0fd",
              "name": "memory_search",
              "arguments": {
                "query": "difference in liver enzyme levels between patient subgroups",
                "limit": 10
              }
            }
          ],
          "tokens_used": 600
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_c2deca2f9f244c09aaf9a0fd",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information in the memory system regarding differences in liver enzyme levels between patient subgroups. The search returned no results, and no further data is available to analyze this question.",
          "tokens_used": 652
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1770,
      "wall_time_ms": 5157.217494095676,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q16_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "negative",
      "prompt": "Are there musculoskeletal or pain-related adverse events associated with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Pain and musculoskeletal endpoints show no drug-related adverse trends. The safety signal is hepatic, confined to the statin co-administered subgroup.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q16_negative",
      "answer_text": "There is no available information in the memory system regarding musculoskeletal or pain-related adverse events associated with LNS-4821 [ref_id: not found].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_c5780cc986a2463e96829468",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 524
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_c5780cc986a2463e96829468",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3c5a6d04393b41e8badbb8c3",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 musculoskeletal adverse events",
                "limit": 10
              }
            }
          ],
          "tokens_used": 609
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3c5a6d04393b41e8badbb8c3",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_72d961f863d64b4cb4113f20",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 pain-related adverse events",
                "limit": 10
              }
            }
          ],
          "tokens_used": 659
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_72d961f863d64b4cb4113f20",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "There is no available information in the memory system regarding musculoskeletal or pain-related adverse events associated with LNS-4821 [ref_id: not found].",
          "tokens_used": 707
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 2499,
      "wall_time_ms": 5889.8722369922325,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q20_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "distractor_resistance",
      "prompt": "Is there any relationship between seroconversion rates and the adverse event pattern?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity measures including seroconversion rates are not related to the hepatotoxicity signal. The adverse events are driven by a CYP3A4-mediated drug-drug interaction with statins.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_023"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q20_distractor",
      "answer_text": "No information was found regarding a relationship between seroconversion rates and adverse event patterns [ref_id: not found]. Therefore, based on the available data, no conclusion can be drawn about such a relationship.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a1d71f46678d47a6b6e647fd",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 519
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a1d71f46678d47a6b6e647fd",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_8ff690902e8a4d85bd91710c",
              "name": "memory_search",
              "arguments": {
                "query": "relationship between seroconversion rates and adverse event patterns"
              }
            }
          ],
          "tokens_used": 595
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_8ff690902e8a4d85bd91710c",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "No information was found regarding a relationship between seroconversion rates and adverse event patterns [ref_id: not found]. Therefore, based on the available data, no conclusion can be drawn about such a relationship.",
          "tokens_used": 650
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1764,
      "wall_time_ms": 4396.133925998583,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  }
]